title: Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]).
abstract: To address the issue of whether probucol reduces clinical events after percutaneous transluminal coronary angioplasty (PTCA), we surveyed clinical status at 1 year after PTCA of 101 patients who had entered the Probucol Restenosis Angioplasty Trial. Repeat angioplasty at index lesions were required in 5 patients in the probucol group and in 12 in the control group, suggesting that probucol administered beginning 4 weeks before PTCA reduces repeat revascularization rates for 1 year.
authors.affiliation: Department of Cardiology, Juntendo University, Tokyo, Japan. daida@med.juntendo.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Daida
authors.forename: Y
authors.initials: Y
authors.lastname: Kuwabara
authors.forename: H
authors.initials: H
authors.lastname: Yokoi
authors.forename: H
authors.initials: H
authors.lastname: Nishikawa
authors.forename: F
authors.initials: F
authors.lastname: Takatsu
authors.forename: Y
authors.initials: Y
authors.lastname: Nakata
authors.forename: Y
authors.initials: Y
authors.lastname: Kutsumi
authors.forename: S
authors.initials: S
authors.lastname: Oshima
authors.forename: S
authors.initials: S
authors.lastname: Nishiyama
authors.forename: S
authors.initials: S
authors.lastname: Ishiwata
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Nishimura
authors.forename: K
authors.initials: K
authors.lastname: Miyauchi
authors.forename: T
authors.initials: T
authors.lastname: Kanoh
authors.forename: H
authors.initials: H
authors.lastname: Yamaguchi
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000517:prevention & control* / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000627:therapeutic use*; D011446:Prospective Studies; D055502:Secondary Prevention
chemical_list: D000924:Anticholesteremic Agents; D011341:Probucol